SignatureFD’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.41K Hold
41
﹤0.01% 3098
2026
Q1
$1.32K Sell
41
-12
-23% -$444 ﹤0.01% 3152
2025
Q4
$2.23K Buy
53
+12
+29% +$484 ﹤0.01% 2938
2025
Q3
$1.41K Hold
41
﹤0.01% 3022
2025
Q2
$1.11K Sell
41
-24
-37% -$695 ﹤0.01% 3000
2025
Q1
$1.93K Sell
65
-14
-18% -$534 ﹤0.01% 2885
2024
Q4
$3.13K Buy
79
+38
+93% +$1.44K ﹤0.01% 2753
2024
Q3
$1.4K Hold
41
﹤0.01% 2923
2024
Q2
$888 Buy
41
+31
+310% +$652 ﹤0.01% 2918
2024
Q1
$222 Sell
10
-225
-96% -$5.49K ﹤0.01% 3090
2023
Q4
$6.46K Buy
+235
New +$5.67K ﹤0.01% 2427
2023
Q3
Sell
-274
Closed -$6.98K 3314
2023
Q2
$6.98K Hold
274
﹤0.01% 2395
2023
Q1
$6.11K Hold
274
﹤0.01% 2430
2022
Q4
$6.5K Hold
274
﹤0.01% 2331
2022
Q3
$5K Sell
274
-18
-6% -$405 ﹤0.01% 2474
2022
Q2
$6K Buy
292
+18
+7% +$364 ﹤0.01% 2409
2022
Q1
$8K Sell
274
-13
-5% -$372 ﹤0.01% 2295
2021
Q4
$12K Sell
287
-24
-8% -$1.06K ﹤0.01% 2049
2021
Q3
$14K Buy
311
+293
+1,628% +$12.8K ﹤0.01% 1922
2021
Q2
$1K Buy
+18
New +$770 ﹤0.01% 2851
2021
Q1
Sell
-24
Closed -$1K 2842
2020
Q4
$1K Buy
+24
New +$1.11K ﹤0.01% 2494

Other funds holding VCYT

SignatureFD's VCYT Position: Q2 2026 in Review

SignatureFD held its Veracyte (VCYT) position steady in Q2 2026 at 41 shares worth $2.41K. The position accounts for ﹤0.01% of the portfolio, ranked #3098.

SignatureFD first reported a position in VCYT in Q4 2020 and has held it in 21 quarters since. The position peaked at $14K in Q3 2021. 57 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • SignatureFD held 41 shares of Veracyte worth $2.41K as of Q2 2026.
  • SignatureFD left its Veracyte share count unchanged in Q2 2026.
  • Veracyte made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3098 holding.
  • SignatureFD first reported a position in Veracyte in Q4 2020 and has held it in 21 quarters since.
  • SignatureFD's Veracyte position peaked at $14K in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.